Aurobindo Pharma Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Aurobindo Pharma Limited Pharmaceutical Export Portfolio Dataset — 81 Products, $1.1B FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Aurobindo Pharma Limited — Pharmaceutical Exporter Profile (2026) | 81 Products, $1.1B Trade | TransData Nexus

Aurobindo Pharma Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $1.1B Total Trade · DGFT Verified

Aurobindo Pharma Limited is an Indian pharmaceutical exporter with a total trade value of $1.1B across 81 products in 18 therapeutic categories. Based on 32,741 verified export shipments from Indian Customs (DGFT) records, Aurobindo Pharma Limited is the #1 Indian exporter in 10 products including Potassium, Clopidogrel, Ondansetron. Top exports include Amoxicillin ($142.4M), Potassium ($97.1M), Pantoprazole ($79.6M).

Aurobindo Pharma Limited — Export Portfolio & Destination Treemap

Aurobindo Pharma Limited pharmaceutical export portfolio — 81 products across 18 therapeutic categories. Source: Indian Customs (DGFT).

Who is Aurobindo Pharma Limited? — Company Overview & Market Position

Aurobindo Pharma Limited, established in December 1986, is a prominent Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana. The company's registered office is located at Plot No. 2, Maitrivihar, Ameerpet, Hyderabad-500038, Telangana, India. Its corporate office is situated at Galaxy, Floors 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500032, Telangana, India.

Aurobindo Pharma is a publicly traded entity listed on the Bombay Stock Exchange (BSE) under the ticker symbol 524804 and on the National Stock Exchange (NSE) as AUROPHARMA. The company's Corporate Identification Number (CIN) is L24239TG1986PLC015190. As of the fiscal year ending March 31, 2024, Aurobindo Pharma reported revenues of approximately $3.83 billion USD. The company employs around 27,707 individuals globally. More information can be found on their official website: www.aurobindo.com.

What Does Aurobindo Pharma Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Amoxicillin$142.4M 2

Product Portfolio — Top 30 by Export Value

Aurobindo Pharma Limited exports 81 pharmaceutical products across 18 therapeutic categories. Market leader (#1 exporter) in 10 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Amoxicillin	Antibiotics	$142.4M	2,848	15.8%	2
2	Potassium	Nutritional Supplements	$97.1M	1,942	10.5%	1
3	Pantoprazole	Gastrointestinal	$79.6M	1,889	5.1%	2
4	Clopidogrel	Cardiovascular	$45.0M	900	14.5%	1
5	Rosuvastatin	Cardiovascular	$41.8M	910	6.7%	6
6	Citalopram	CNS & Psychiatric	$41.4M	1,455	11.0%	2
7	Ondansetron	Gastrointestinal	$41.0M	985	25.8%	1
8	Sertraline	CNS & Psychiatric	$40.8M	930	6.1%	2
9	Escitalopram	CNS & Psychiatric	$33.4M	823	11.5%	2
10	Atorvastatin	Cardiovascular	$33.2M	879	3.1%	7
11	Gabapentin	CNS & Psychiatric	$26.9M	891	3.1%	10
12	Cefuroxime	Advanced Antibiotics	$26.5M	972	14.3%	2
13	Metformin	Diabetes & Endocrine	$21.8M	547	3.2%	6
14	Pioglitazone	Diabetes & Endocrine	$19.2M	708	40.7%	1
15	Piperacillin	Advanced Antibiotics	$18.8M	375	15.6%	1
16	Metoprolol	Cardiovascular	$18.7M	407	1.8%	6
17	Losartan	Cardiovascular	$18.1M	582	4.3%	4
18	Ramipril	Cardiovascular	$17.3M	1,087	14.8%	3
19	Cefpodoxime	Advanced Antibiotics	$15.4M	308	13.8%	2
20	Cephalexin	Antibiotics	$14.8M	330	3.4%	3
21	Iron	Vitamins & Supplements	$13.4M	268	1.7%	5
22	Spironolactone	Diuretics	$13.4M	268	4.2%	3
23	Sodium	Nutritional Supplements	$13.2M	341	3.7%	5
24	Terbinafine	Antifungals	$12.7M	352	37.3%	1
25	Clindamycin	Antibiotics	$12.6M	251	10.4%	2
26	Fluoxetine	CNS & Psychiatric	$12.2M	287	4.6%	4
27	Simvastatin	Cardiovascular	$11.9M	720	6.8%	5
28	Ciprofloxacin	Antibiotics	$11.4M	250	3.8%	5
29	Loratadine	Antihistamines & Allergy	$10.8M	265	6.3%	2
30	Cefixime	Advanced Antibiotics	$10.7M	268	4.6%	3

Aurobindo Pharma Limited exports 81 pharmaceutical products across 18 therapeutic categories with a total export value of $1.1B. The company is the #1 Indian exporter in 10 products: Potassium, Clopidogrel, Ondansetron, Pioglitazone, Piperacillin and 1 more. The top category is Cardiovascular (20.3% of portfolio), followed by Antibiotics (17.7%), reflecting a diversified portfolio where the top 5 products account for only 36.5% of total value.

Showing top 30 of 81 products. Contact us for complete data.

Aurobindo Pharma Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Aurobindo Pharma operates multiple manufacturing facilities across India and internationally. In India, the company has 11 units dedicated to Active Pharmaceutical Ingredients (APIs) and 10 units for formulations. Internationally, it operates three formulation units in the USA, one in Brazil, and one in Portugal. These facilities are designed to meet the requirements of both advanced and emerging markets, producing a wide range of pharmaceutical products.

The company's leadership team includes K. Nityananda Reddy serving as Vice Chairman and Managing Director, and Santhanam Subramanian as Chief Financial Officer. Other key executives include M. Madan Mohan Reddy as Whole Time Director and P. Sarath Chandra Reddy as Whole Time Director. (craft.co)

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Aurobindo Pharma Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Aurobindo Pharma has established a significant presence in major regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities have received approvals from key regulatory bodies such as the US Food and Drug Administration (FDA), UK's Medicines and Healthcare products Regulatory Agency (MHRA), Australia's Therapeutic Goods Administration (TGA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA).

In the United States, Aurobindo's subsidiary, Aurobindo Pharma USA Inc. (APUSA), has been instrumental in distributing a broad line of generic pharmaceuticals. As of April 2024, APUSA was ranked #1 in terms of prescriptions for generic oral solids. In the European Union, the company operates in ten countries, including France, Germany, and the UK, with a portfolio of over 550 International Nonproprietary Names (INNs), addressing more than 80% of the European pharmaceutical market. Notably, in May 2025, Aurobindo's subsidiary, CuraTeQ Biologics, received marketing authorization from the UK's MHRA for Zefylti, a filgrastim biosimilar.

2Emerging Markets

Aurobindo Pharma has been actively expanding its presence in emerging markets across Africa, Latin America, and Southeast Asia. The company exports to over 150 countries, with more than 90% of its revenues derived from international operations. In October 2025, Aurobindo's subsidiary, Eugia Pharma B.V., incorporated a new subsidiary in Chile, Eugia Pharma Chile SpA, to strengthen its footprint in the Latin American pharmaceutical market. (scanx.trade) Additionally, Aurobindo's manufacturing facilities have received approvals from the World Health Organization (WHO), facilitating access to various emerging markets.

Aurobindo Pharma Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Aurobindo Pharma has multiple manufacturing facilities registered with the U.S. Food and Drug Administration (FDA). The company has a substantial number of approved Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs), reflecting its extensive portfolio in the U.S. market. However, specific counts of these approvals are not readily available in the public domain.

The FDA has conducted several inspections of Aurobindo's facilities, resulting in observations and regulatory actions. For instance, in January 2026, the FDA inspected Unit-VII, an oral solid dosage manufacturing facility in Jedcherla, Telangana, issuing a Form 483 with nine procedural observations. Similarly, in February 2026, Unit-I of Eugia Pharma Specialities, a wholly-owned subsidiary, received four observations following an FDA inspection. These observations were procedural, and the company committed to addressing them within stipulated timelines.

2WHO & EU GMP

Aurobindo Pharma's commitment to quality is evident through its compliance with international standards. The company has obtained certifications from the World Health Organization's Good Manufacturing Practices (WHO-GMP) and the European Union's Good Manufacturing Practice (EU GMP). Additionally, Aurobindo holds certificates from the European Directorate for the Quality of Medicines (EDQM), facilitating its product distribution across various global markets.

Aurobindo Pharma Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the cardiovascular segment, Aurobindo faces competition from Torrent Pharmaceuticals, known for its focus on cardiovascular therapies, and Lupin Limited, which has a strong presence in this area. In the antibiotics category, Sun Pharmaceutical Industries, India's largest pharmaceutical company, and Cipla Limited, recognized for their extensive antibiotic portfolios, are key competitors. In the CNS & psychiatric segment, Sun Pharma and Dr. Reddy’s Laboratories are notable competitors, both offering a range of neuropsychiatric medications.

Aurobindo's market share in its top products indicates a strong position:

Amoxicillin: $142.4 million in exports, ranking #2 with a 15.8% market share.

Potassium: $97.1 million in exports, ranking #1 with a 10.5% market share.

Pantoprazole: $79.6 million in exports, ranking #2 with a 5.1% market share.

Clopidogrel: $45.0 million in exports, ranking #1 with a 14.5% market share.

Buyer Due Diligence Brief — Evaluating Aurobindo Pharma Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Due Diligence Checklist

Verify Regulatory Certifications:

US FDA: Confirm the current status of FDA approvals for Aurobindo's manufacturing facilities.

WHO-GMP: Ensure the company holds valid WHO-GMP certifications.

EU GMP: Check for EMA GMP certifications, particularly for facilities involved in biosimilar production.

Assess Financial Health:
Review recent financial statements and stock performance to gauge financial stability.

Evaluate Regulatory Compliance:
Investigate any recent FDA warning letters or observations and the company's responses.

Frequently Asked Questions — Aurobindo Pharma Limited

How many pharmaceutical products does Aurobindo Pharma Limited export from India?

How many pharmaceutical products does Aurobindo Pharma Limited export from India? Aurobindo Pharma Limited exports 81 finished pharmaceutical formulations from India, spanning 18 therapeutic categories. These include tablets, capsules, syrups, and injections, catering to a diverse range of medical needs.

What is Aurobindo Pharma Limited's total pharmaceutical export value?

What is Aurobindo Pharma Limited's total pharmaceutical export value? Between 2022 and 2026, Aurobindo Pharma Limited achieved a total export value of $1.1 billion USD. This substantial figure underscores the company's significant presence in the global pharmaceutical market.

What are Aurobindo Pharma Limited's top exported pharmaceutical formulations?

What are Aurobindo Pharma Limited's top exported pharmaceutical formulations? The company's top five exported products are Amoxicillin ($142.4 million, 15.8% market share), Potassium ($97.1 million, 10.5% market share), Pantoprazole ($79.6 million, 5.1% market share), Clopidogrel ($45.0 million, 14.5% market share), and Rosuvastatin ($41.8 million, 6.7% market share). These products collectively account for 36.5% of the company's export portfolio.

Which therapeutic categories does Aurobindo Pharma Limited specialize in?

Which therapeutic categories does Aurobindo Pharma Limited specialize in? Aurobindo Pharma Limited specializes in several therapeutic categories, with the top three being Cardiovascular (20.3% of exports), Antibiotics (17.7%), and Central Nervous System & Psychiatric medications (14.2%). This diverse specialization reflects the company's commitment to addressing a wide range of health conditions.

Get Full Aurobindo Pharma Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

Aurobindo Pharma Limited

Aurobindo Pharma Limited — Export Portfolio & Destination Treemap

Who is Aurobindo Pharma Limited? — Company Overview & Market Position

What Does Aurobindo Pharma Limited Export? — Product Portfolio Analysis

Top Products by Export Value

Aurobindo Pharma Limited Therapeutic Categories — 18 Specializations

Product Portfolio — Top 30 by Export Value

All 81 Products

Key Metrics

Top Categories

Top Export Routes

Related Analysis

Need Detailed Data?

Aurobindo Pharma Limited — Corporate Profile & Information

1Corporate Overview

2Manufacturing Facilities

Where Does Aurobindo Pharma Limited Export? — Destination Intelligence

1Regulated Markets

2Emerging Markets

Aurobindo Pharma Limited — Manufacturing & Regulatory Profile

1FDA Status

2WHO & EU GMP

Aurobindo Pharma Limited — Competitive Positioning Among Indian Pharma Exporters

1Competitive Landscape

Buyer Due Diligence Brief — Evaluating Aurobindo Pharma Limited as a Supplier

1Due Diligence Checklist

Frequently Asked Questions — Aurobindo Pharma Limited

How many pharmaceutical products does Aurobindo Pharma Limited export from India?

What is Aurobindo Pharma Limited's total pharmaceutical export value?

What are Aurobindo Pharma Limited's top exported pharmaceutical formulations?

Which therapeutic categories does Aurobindo Pharma Limited specialize in?

Get Full Aurobindo Pharma Limited Export Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Data Source & Methodology

3Geographic Strategy

3CDSCO & Indian Regulatory

4Recent Regulatory Actions

2Key Differentiators

3Strategic Position

Is Aurobindo Pharma Limited FDA approved for pharmaceutical exports?

What countries does Aurobindo Pharma Limited export pharmaceuticals to?

How does Aurobindo Pharma Limited compare to other Indian pharmaceutical exporters?

Is Aurobindo Pharma Limited WHO-GMP certified?

What is Aurobindo Pharma Limited's market share in Indian pharmaceutical exports?

How to verify Aurobindo Pharma Limited as a pharmaceutical supplier?

Analysis Methodology